产前贝他他给药对胎盘血管抵抗的作用
1Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. Euan.Wallace@med.monash.edu.au
Lancet (London, England)
|May 5, 1999
概括
贝塔梅他的使用改善了胎盘血流在怀孕缺少终端-透气流的怀孕,减少胎盘血管抵抗. 需要进一步的研究来确定这种干预是否有利于胎儿的结果.
科学领域:
- 周围生理学 周围生理学
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 胎儿生理学 胎儿生理学
背景情况:
- 高水平的胎盘血管阻力是胎儿生长限制和围产期死亡的一个关键因素.
- 目前的管理重点是监测和分娩,缺乏改善胎盘血流的治疗选择.
- 胎盘皮质激素释放激素 (CRH) 是一种潜在的血管扩张剂,皮质类固醇可以增强其分泌.
研究的目的:
- 为了研究皮质类固醇对胎儿胎盘血流的影响,在怀孕时胎盘血管抵抗增加.
- 为了确定贝他他的管理是否可以降低胎盘血管阻力在缺席的末端透气流 (AEDF) 的情况下.
主要方法:
- 动脉流速波形 (FVWs) 在28个怀孕中与AEDF的回顾性审查.
- 在使用脉冲波多普勒超声学评估贝塔梅他给药前后评估FVW.
- 收集的数据包括表现时的妊娠年龄和动脉透静流量的变化.
主要成果:
- 在68%的怀孕中,动脉的舒张流在贝他美给药后的24小时内恢复.
- 观察到的胎盘血管阻力下降持续了平均3天.
- 没有注意到有或没有流量回归的胎儿在分娩时的妊娠年龄或出生体重之间存在显著差异.
结论:
- 贝塔梅他治疗与胎盘血管抵抗的降低有关,在怀孕期间,动脉AEDF.
- 这种效应可能是由于胎盘CRH分泌量增加而引起的.
- 这种干预对胎儿后果的临床益处或危害仍未确定.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Development of Blood Vessels
The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
Fetal Circulation
Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...


